Premium
Co(II), Ni(II), Cu(II) and Zn(II) complexes of isatinyl‐2‐aminobenzoylhydrazone: synthesis, characterization and anticancer activity
Author(s) -
Hunoor Rekha S.,
Patil Basavaraj R.,
Badiger Dayananda S.,
V. M. Chandrashekhar,
Muchchandi I. S.,
Gudasi Kalagouda B.
Publication year - 2015
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.3252
Subject(s) - chemistry , monobasic acid , octahedral molecular geometry , isatin , ligand (biochemistry) , chelation , tetrahedral molecular geometry , ehrlich ascites carcinoma , proton nmr , stereochemistry , hydrazone , crystallography , in vitro , polymer chemistry , crystal structure , inorganic chemistry , organic chemistry , biochemistry , receptor
This article describes the synthesis, structural aspects and biological studies of Co(II), Ni(II), Cu(II) and Zn(II) complexes of a new hydrazone derived from the condensation of isatin and 2‐aminobenzoylhydrazide. The ligand is well characterized using 1 H NMR, 13 C NMR, 2D HETCOR, mass and IR spectral studies. The chelating tendency of the ligand towards transition metal ions is established using analytical and spectral studies, which reveal the monobasic tridentate nature of the ligand. Octahedral geometry for Co(II), Cu(II) and Zn(II) and tetrahedral geometry for Ni(II) are tentatively proposed. All the synthesized compounds were screened for in vitro anticancer activity against Ehrlich ascites carcinoma and human cancer cell lines (adenocarcinoma HT29, kidney cancer cell line K293 and breast cancer cell line MDA231) using tryphan blue exclusion method and MTT assay. Copyright © 2014 John Wiley & Sons, Ltd.